Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of Subcutaneously Administered Veltuzumab (hA20) in Patients With CD20+ Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

NCT00546793 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT00546793
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00546793 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of Subcutaneously Administered Veltuzumab (hA20) in Patients With CD20+ Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
Lead sponsor
Gilead Sciences
Phase
Phase 1/2
Overall status
Completed
Start date
January 31, 2008
Completion date
March 31, 2013
Enrollment
32 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

cll, leukemia, b-cell, chronic, leukemia, lymphocytic, chronic, leukemia, prolymphocytic, leukemia, small lymphocytic, lymphoma, b-cell, lymphoma, follicular, lymphoma, intermediate-grade, lymphoma, large-cell, lymphoma, low-grade, lymphoma, lymphoplasmacytoid, cll, lymphoma, mixed-cell, lymphoma, non-hodgkin, lymphoma, small lymphocytic, lymphoma, small-cell, lymphoplasmacytoid lymphoma, cll, nhl, sll